Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

NCT00481845 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Breast Cancer

Interventions

DRUG: Vandetanib
DRUG: Anastrozole

Sponsor

Stanford University

Collaborators

[object Object]